IQVIA SOLUTIONS ASIA PTE. LTD.
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Computer Processing and Data Preparation and Processing Services, Information Retrieval Services), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about IQVIA SOLUTIONS ASIA PTE. LTD.
Live alerts from global media, monitored by Business Radar
2025-05-05 (diariofarma.com)
Health launches its 'wait', which cuts 176 days the deadline for financing innovation since 2020 | @
A few days after Efpia publishes the WAIT report, the Ministry of Health has advanced its data on innovative drug financing deadlines, highlighting a drop in waiting times and greater early availability for patients. With this report, Health also wants to advance in transparency and advertising of accessible public information.
Read more
2025-04-14 (healthnews.pt)
Iqvia and Ema join the forces to combat medicine scarcity in Europe |
IQVIA, one of the leading global suppliers of Clinical Research and Health Intelligence services, announced the signing of a contract with the European Medicines Agency (EMA) to provide access to its owner databases of drug consumption.
Read more
2025-03-20 (centerforbiosimilars.com)
Smart Tendering Policies Unlock Greater Biosimilar Savings
Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.
Read more
2025-03-19 (industryintel.com)
Cardinal Health celebrates decade of biosimilar medicines in United States; healthcare system saves US$36 billion as 70 biosimilars gain approval since 2015 | Industry Intelligence Inc.
2025 signifies a 10-year landmark in healthcare when the first commercially available biosimilar was made available in the U.S. and launched a bra
Read more
2022-03-16 (jdsupra.com)
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline Updated March 14, 2022
FDA and EMA both approve additional biosimilar versions of Humira® (adalimumab). FDA also approves its third biosimilar version of...
Read more